Breaking Finance News

A statement released earlier today by Brean Capital about TG Therapeutics Inc (NASDAQ:TGTX) bumps the target price to $28.00

Having a price of $8.10, TG Therapeutics Inc (NASDAQ:TGTX) traded -0.24% lower on the day. With the last stock price up 13.42% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. TGTX has recorded a 50-day average of $7.01 and a two hundred day average of $7.37. Trade Volume was down over the average, with 218,582 shares of TGTX changing hands under the typical 315,926

Brean Capital upped the price target of TG Therapeutics Inc (NASDAQ:TGTX) to $28.00 reporting a possible upside of 2.46%.

On 08/12/2015, H.C. Wainwright released a statement about TG Therapeutics Inc (NASDAQ:TGTX) upped the target price from $0.00 to $22.00 that suggested an upside of 0.37%.

Recent Performance Chart

TG Therapeutics Inc (NASDAQ:TGTX)

TG Therapeutics Inc has with a one year low of $5.41 and a one year high of $14.87 and has a market capitalization of $0.

General Company Details For TG Therapeutics Inc (NASDAQ:TGTX)

TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.